Duchenne Muscular Dystrophy
Emflaza is approved for the treatment of Duchenne muscular dystrophy regardless of genetic etiology.
Patients who received ACE inhibitors showed a slower progression of myocardial fibrosis and fewer cardiovascular events.
Eteplirsen is the first drug approved in the US for the treatment of DMD.
Over 52 weeks, patients taking deflazacort experienced improved muscle strength and less weight gain compared with prednisone.
Deflazacort is intended to help improve muscle strength and other functional outcomes in DMD regardless of genetic etiology.
The DMD space is becoming increasingly crowded as the FDA works to identify a drug worth approving.
This is the second extension requested by the FDA.
The panel took a similar stance in the fall when it did not recommend Biomarin's drisapersen for the treatment of DMD.
After a lukewarm review, the FDA has officially denied the NDA for drisapersen.
Translarna (ataluren) is for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD).
Researchers recommend that follow-up protocols be developed for those with elevated CK but negative DMD gene testing.
The committee cited a lack of consistent clinical trial results as well as concerns over serious adverse events.
Researchers have linked the Jagged1 gene to a much milder form of muscular dystrophy in golden retrievers.
The FDA is set to make a decision on the NDA by late February, 2016.
A deflazacort regimen appeared to slow loss of ambulation, but not without several side effects.
The conditions are similar, but differ in rate of progression and age of onset.
Neurology Advisor Articles
- Cannabis: Current Evidence and Research Recommendations
- Addressing Gender Differences in Concussion Diagnosis and Treatment
- Sphenopalatine Ganglion Stimulation May Help Treat, Prevent Cluster Headache
- Relapsing-Remitting Multiple Sclerosis Halted With Immunosuppression, Stem Cell Transplant
- Maternal Antiepileptic Use and Risk for Major Congenital Malformations in Offspring
- Persistent Asthma May Increase Migraine Risk in Children
- Updated Guidelines for Treatment of Low Back Pain
- Antiretroviral Therapy May Improve Neurodevelopmental Outcomes in HIV-Infected Infants
- Head Impacts in Soccer Lead to Moderate to Severe CNS Symptoms
- The Handoff: Your Week in Neurology News - 2/16/17